Clinical Trial Update: ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of Treatment [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the oral ELB139 in patients with panic disorder under CO2 challenge after a single dose and one week of treatment was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Panic Disorder

Drugs mentioned

• ELB139

Snippet

Sponsor: elbion AG | Conditions: Panic Disorder | Phase 2 | Status: TERMINATED